COVID-19 and its psychological consequences: Beware of the respiratory subtype of panic disorder

Javelot, Hervé; Weiner, Luisa; Hingray, Coraline; Freire, Rafael C.; Nardi, Antônio Egídio

doi:10.1016/j.resp.2020.103530

Cited by 7 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to studies pre-COVID we did find a reduction in remission rate from post-treatment (72.1%) to follow-up (62.3%), and long-time follow-up of this sample is thus warranted. Some patients with PD may also be more vulnerable for relapse during the COVID-pandemic, since the virus affects the respiratory system which also is where the fear originates for many PD-patients [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

The Bergen 4-day treatment for panic disorder: adapting to COVID-19 restrictions with a hybrid approach of face-to-face and videoconference modalities

et al. 2023

View full text Add to dashboard Cite

Background The Bergen 4-day treatment (B4DT) is a concentrated exposure-based therapy that has been shown to be effective in the treatment of anxiety disorders. The current study sought to examine the effectiveness of B4DT for panic disorder (PD), when delivered with a combination of face-to-face sessions and videoconferencing. Methods Treatment was delivered to 50 patients from April 2020 to May 2021. Because of regulations during the pandemic, a significant portion of the treatment was conducted via videoconference. The primary outcome measure was the clinician-rated Panic Disorder Severity Scale (PDSS), and secondary measures included patient-rated symptoms of panic disorder, agoraphobia, generalized anxiety, depression, and treatment satisfaction. Changes in symptom levels over time were estimated using multilevel models. Results Patients showed a significant reduction in clinician-rated symptoms of panic disorder (Measured by PDSS) from before treatment to post treatment (d = 2.18) and 3-month follow-up (d = 2.01). At three months follow-up 62% of patients were classified as in remission, while 70% reported a clinically significant response. We also found a reduction in symptoms of depression and generalized anxiety, and the patients reported high satisfaction with the treatment. Conclusion The current study suggests that B4DT delivered in a combination of videoconference and face-to-face meetings may be a useful treatment approach. As the study is uncontrolled, future studies should also include more strictly designed investigations.

show abstract

Section: Discussionmentioning

confidence: 99%

The Bergen 4-day treatment for panic disorder: adapting to COVID-19 restrictions with a hybrid approach of face-to-face and videoconference modalities

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Имеются данные, что пациенты с коморбидными заболеваниями и иммуносупрессией более подвержены развитию когнитивных нарушений, тревоги и депрессии [35]. Респираторные симптомы COVID-19 могут обусловить развитие панического расстройства [36]. Развитие аффективных расстройств в постковидном периоде частично объясняется системным воспалением вследствие COVID-19, когда реакция гипервоспаления в острой фазе продолжается в персистирующее хроническое воспаление, являющееся патогенетическим механизмом расстройств настроения [37].…”

Section: возможные механизмы развития постковидных нейропсихиатрическ...unclassified

Neuropsychiatric consequences of COVID-19

Петрова

2022

Juvenis scientia

View full text Add to dashboard Cite

Обзор литературы посвящен постковидным нейропсихиатрическим расстройствам. В статье раскрывается понятие постковидного синдрома, приводятся определения NICE и ВОЗ, дается характеристика клинической картины с системным поражением организма. Приводятся данные о росте психиатрической заболеваемости в различные сроки после перенесенной коронавирусной инфекции, включая депрессию, тревогу, когнитивные нарушения, астению. В качестве основной характеристики постковидного синдрома описан астеноневротический симптомокомплекс с выраженной астенией и когнитивной дисфункцией, к которому нередко присоединяется затяжная тревожно-депрессивная симптоматика. Когнитивные нарушения в рамках постковидного синдрома представлены преимущественно нарушениями памяти, снижением способности к концентрации внимания, ухудшением исполнительских функций независимо от возраста и предшествующего когнитивного снижения. Отмечено, что делирий в остром периоде коронавирусной инфекции является значимым фактором риска развития когнитивных нарушений в постковидном периоде. Описываются предполагаемые механизмы и факторы риска нейропсихиатрических последствий COVID-19, при этом подчеркивается значение системного воспаления, как ведущего патогенетического механизма постковидных психических расстройств.

show abstract

“…Finally, concerning panic disorder and the COVID-19 pandemic, it would be interesting to follow both the overall evolution of this disorder, but also the specific prevalence rate of the respiratory subtype. While several studies have investigated the psychological consequences of the current pandemic, to date very few studies have focused on panic disorder specifically [32,163]. This might seem surprising given the predominance of respiratory symptoms in both COVID-19 and panic disorder, on the one hand, and the generalized fear of contamination and fear of suffocation heightened by the pandemic, on the other hand [32,163].…”

Section: Anxiety Disordersmentioning

confidence: 99%

“…While several studies have investigated the psychological consequences of the current pandemic, to date very few studies have focused on panic disorder specifically [32,163]. This might seem surprising given the predominance of respiratory symptoms in both COVID-19 and panic disorder, on the one hand, and the generalized fear of contamination and fear of suffocation heightened by the pandemic, on the other hand [32,163]. Salbutamol, a short-acting β-stimulant can be overused in many situations; in patients with asthma, in comorbid situations with asthma and panic disorder (or the latter disorder alone misdiagnosed as asthma) or in the respiratory subtype of panic disorder [33].…”

Section: Anxiety Disordersmentioning

confidence: 99%

Psychotropics and COVID-19: An analysis of safety and prophylaxis

et al. 2021

View full text Add to dashboard Cite

The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes should be made to pharmacological treatments prescribed to mental health patients? Secondly, are there any positive side effects of these substances against SARS-CoV-2? Our aim was to analyze usage safety of psychotropics during COVID-19, therefore herein we have studied: (i) the risk of symptomatic complications of COVID-19 associated with the use of these drugs, notably central nervous system activity depression, QTc interval enlargement and infectious and thromboembolic complications, (ii) the risk of mistaking the iatrogenic impact of psychotropics with COVID-19 symptoms, causing diagnostic error. Moreover, we provided a summary of the different information available today for these risks, categorized by mental health disorder, for the following: schizophrenia, bipolar disorder, anxiety disorder, ADHD, sleep disorders and suicidal risk. The matter of psychoactive substance use during the pandemic is also analyzed in this paper, and guideline websites and publications for psychotropic treatments in the context of COVID-19 are referenced during the text, so that changes on those guidelines and eventual interaction between psychotropics and COVID-19 treatment medication can be reported and studied. Finally, we also provide a literature review of the latest known antiviral properties of psychotropics against SARS-CoV-2 as complementary information.

show abstract

COVID-19 and its psychological consequences: Beware of the respiratory subtype of panic disorder

Abstract: Highlights COVID-19 could increase the rates of the respiratory subtype of panic disorder.

Cited by 7 publications

References 6 publications

The Bergen 4-day treatment for panic disorder: adapting to COVID-19 restrictions with a hybrid approach of face-to-face and videoconference modalities

The Bergen 4-day treatment for panic disorder: adapting to COVID-19 restrictions with a hybrid approach of face-to-face and videoconference modalities

Neuropsychiatric consequences of COVID-19

Psychotropics and COVID-19: An analysis of safety and prophylaxis

Contact Info

Product

Resources

About